ArticleJournal of pharmaceutical analysis2026
Diosgenin presents a novel role in promoting diabetic wound healing: A mechanism involving Sirt6/Nrf2-mediated inhibition of ferroptosis.
Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delayed wound healing in patients with diabetes is frequently caused by the dysfunction of human umbilical vein endothelial cells (HUVECs). Under high-glucose and high-fat (HGHF) conditions, the microenvironment induces uncontrolled lipid peroxidation and subsequent iron-dependent ferroptosis. Diosgenin (DG), a steroidal saponin extracted from herbs, including wild yam, exhibits diverse pharmacological activities. The present study aimed to investigate the role and underlying mechanism of DG in HGHF-induced ferroptosis and diabetic wound (DW) healing. A DW model was established in mice by intraperitoneal injection of streptozotocin (STZ). HUVECs were cultured under HGHF conditions to induce the diabetic microenvironment. C11-BODIPY, FerroOrange probes, and hematoxylin-eosin (H&E)/Masson staining were used to determine lipid peroxidation, iron ion levels, and histological changes, respectively. Results demonstrated that DG alleviated HGHF-induced ferroptosis, as evidenced by reduced malondialdehyde (MDA), lipid peroxidation, and mitochondrial reactive oxygen species (ROS) levels, and increased glutathione (GSH) levels. Additionally, DG upregulated the expression of the anti-ferroptotic protein glutathione peroxidase 4 (GPX4), promoted angiogenesis, and accelerated wound healing in diabetic mice. Network pharmacology analysis identified the sirtuin 6/nuclear factor erythroid 2-related factor 2 (Sirt6/Nrf2) pathway as a potential target of DG, a finding validated by mechanistic studies. Silencing Sirt6 in HUVECs negated the protective effect of DG against ferroptosis. In conclusion, DG mitigates ferroptosis and promotes DW healing, at least partially through activating the Sirt6/Nrf2 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.